Pharmacologic Manipulation of Bleeding and Thrombosis
Treatment
Ximelagatran vs. low-molecular-weight heparin and warfarin for the treatment of deep venous thrombosis: a randomized trial.
Fiessinger JN, Huisman MV, Davidson BL, et al.
JAMA. 2005;293:681-689.
Description: Key, randomized, double-blinded study of 2489 patients with acute DVT, establishing therapeutic equivalence of the new oral direct thrombin inhibitor ximelagatran compared with enoxaparin/warfarin.
PubMed citation number: 15701909
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.
Buller HR, Davidson BL, Decousus H, et al; Matisse investigators.
N Engl J Med. 2003;349:1695-1702.
Description: Randomized open-label trial of 2213 patients with acute pulmonary embolism, establishing the comparable efficacy and safety profile of the new factor Xa inhibitor fondaparinux compared with unfractionated heparin.
PubMed citation number: 14585937
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
Buller HR, Davidson BL, Decousus H, et al; Matisse investigators.
Ann Intern Med. 2004;140:867-873.
Description: Randomized, multicenter trial of 2205 patients with acute deep venous thrombosis, establishing the noninferiority of once-daily fondaparinux compared with twice-daily enoxaparin for initial therapy.
PubMed citation number: 15172900
A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis: a Phase II evaluation.
Buller HR, Cohen AT, Lensing AWA, et al.
J Thromb Haemost. 2004;2:47-53.
Description: Randomized trial of 659 patients demonstrating comparable efficacy and safety of the synthetic factor Xa inhibitor idraparinux (SanOrg34006) versus warfarin in secondary prevention of DVT. The predictable pharmacokinetics of idraparinux permit once-weekly subcutaneous dosing, with major potential implications for patient care if these results are confirmed.
PubMed citation number: 14717965
Review
A pharmacologic overview of current and emerging anticoagulants.
Nutescu EA, Shapiro NL, Chevalier A, Amin AN.
Cleve Clin J Med. 2005;72:S2-S6.
Description: An updated overview of emerging anticoagulant drugs, including low-molecular-weight heparins, factor Xa inhibitors, and direct thrombin inhibitors.
PubMed citation number: 15853173
New anticoagulants.
Hirsh J, O’Donnell M, Weitz JI.
Blood. 2005;105:453-463.
Description: A timely review of recent landmark phase 3 trials involving emerging factor Xa inhibitors and direct thrombin inhibitors for various cardiac, orthopedic, and hematologic indications.
PubMed citation number: 15191946
Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review.
Levi M, Peters M, Buller HR.
Crit Care Med. 2005;33:883-890.
Description: A systematic review of the pharmacologic use of the prohemostatic agent recombinant factor VIIa for treatment of severe bleeding not related to underlying coagulation system disorders.
PubMed citation number: 15818119
The use of vitamin K in patients on anticoagulant therapy: a practical guide.
Hanslik T, Prinseau J.
Am J Cardiovasc Drugs. 2004;4:43-55.
Description: A practical review of the use of vitamin K in reversal overanticoagulation.
PubMed citation number: 14967065